Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Fiche publication
Date publication
juillet 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume
Tous les auteurs :
Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P
Lien Pubmed
Résumé
BACKGROUND: Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced, well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors of grade 1 or 2 (a tumor proliferation index [on staining for the Ki-67 antigen] of
Référence
N Engl J Med. 2014 Jul 17;371(3):224-33